# Nvelop Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/nvelop-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.nveloptx.com
- Total disclosed funding: $25M
- Latest round: Seed (Jul 21, 2022)
- Investors on record: 6

## About

Founded in 2022 by Keith Joung and David Liu, and based in Massachusetts, US, Nvelop Therapeutics operates as a biotechnology research company that develops genetic medicines to treat patients with previously undruggable diseases. In December 2024, Chroma Medicine, Inc., a portfolio company of Atlas Venture, Newpath Partners, Sofinnova Partners, Casdin Capital, etc., merged with Nvelop Therapeutics, a portfolio company of Newpath Partners, Atlas Venture, F-Prime Capital, 5AM Ventures, etc., to form nChroma Bio. The firm as of December 2024, is led by its CEO, Jeff Walsh.

Nvelop Therapeutics focuses on advancing genetic medicine through its delivery platforms, specifically DLVR-X and DLVR-M. These platforms utilize modular, non-viral vehicles engineered for tissue-specific delivery and in vivo editing, addressing critical limitations in current gene therapy delivery technologies. DLVR-X is designed to deliver diverse therapeutic cargoes, including transiently expressed ribonucleoproteins, while minimizing off-target effects. In contrast, DLVR-M emphasizes a fully humanized architecture to enhance targeting profiles and reduce immunogenicity. The geographical markets for Nvelop's product offerings include North America, Europe, and select regions in Asia, targeting research institutions, biotechnology companies, and pharmaceutical manufacturers.

## Funding rounds

- Seed, Jul 21, 2022, $25M — ARCH Venture Partners, Atlas Venture, 5AM Ventures, F-Prime Capital, GV, Newpath Partners

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Seed
- Atlas Venture (https://capitalatlas.ai/funds/atlas-venture) — Seed
- 5AM Ventures (https://capitalatlas.ai/funds/5am-ventures) — Seed
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Seed
- GV (https://capitalatlas.ai/funds/gv) — Seed
- Newpath Partners (https://capitalatlas.ai/funds/newpath-partners) — Seed